Exagen (XGN) Stock Overview
Designs, develops, and commercializes various testing products under the AVISE brand in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Exagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.85 |
| 52 Week High | US$12.23 |
| 52 Week Low | US$2.38 |
| Beta | 1.54 |
| 1 Month Change | 10.03% |
| 3 Month Change | 41.07% |
| 1 Year Change | 372.11% |
| 3 Year Change | 393.75% |
| 5 Year Change | -23.50% |
| Change since IPO | -36.22% |
Recent News & Updates
Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now
Sep 13Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Aug 05
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 01Recent updates
Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now
Sep 13Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Aug 05Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 01Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The Industry
May 18Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75
May 09Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Apr 26
Biomarker Launch And AVISE CTD Expansion Will Drive Future Success
New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price Rise
Apr 03Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
Mar 04Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Feb 05Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 22Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Sep 06Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Aug 07Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
Jul 13Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
May 21Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Mar 26Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Mar 22Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
Jul 21Exagen appoints John Aballi as CEO
Oct 17Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Aug 10Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
Jul 26Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Apr 05Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Aug 06Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price
Apr 07Is Exagen (NASDAQ:XGN) Using Too Much Debt?
Mar 03Shareholder Returns
| XGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 1.3% | 2.6% |
| 1Y | 372.1% | 3.4% | 19.0% |
Return vs Industry: XGN exceeded the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: XGN exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| XGN volatility | |
|---|---|
| XGN Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XGN's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 212 | John Aballi | www.exagen.com |
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
Exagen Inc. Fundamentals Summary
| XGN fundamental statistics | |
|---|---|
| Market cap | US$261.62m |
| Earnings (TTM) | -US$16.98m |
| Revenue (TTM) | US$58.86m |
Is XGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XGN income statement (TTM) | |
|---|---|
| Revenue | US$58.86m |
| Cost of Revenue | US$23.89m |
| Gross Profit | US$34.98m |
| Other Expenses | US$51.96m |
| Earnings | -US$16.98m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 04, 2025
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 59.42% |
| Net Profit Margin | -28.85% |
| Debt/Equity Ratio | 109.2% |
How did XGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/29 03:15 |
| End of Day Share Price | 2025/10/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exagen Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |